^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MUC5B mutation

    i
    Other names: MUC5B, Mucin 5B, Oligomeric Mucus/Gel-Forming, High Molecular Weight Salivary Mucin MG1, Mucin 5, Subtype B, Tracheobronchial, Sublingual Gland Mucin, Mucin-5B, MUC-5B, MUC5, MG1, Mucin-5 Subtype B, Tracheobronchial, Cervical Mucin MUC5B, Cervical Mucin, MUC5B, MUC9
    Entrez ID:
    727897
    Related biomarkers:
    Expression
    8ms
    Characterizing and forecasting neoantigens-resulting from MUC mutations in COAD. (PubMed, J Transl Med)
    Together, our findings establish the immunogenicity and therapeutic potential of mutant MUC family-derived neoantigens. Through combining the tools of TSNAdb and DAI, a group of novel MUCmut neoantigens were identified as potential targets for immunotherapy.
    Journal • Tumor mutational burden • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • MUC16 (Mucin 16, Cell Surface Associated) • MUC4 (Mucin 4, Cell Surface Associated) • MUC13 (Mucin 13) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming) • MUC2 (Mucin 2) • MUC20 (Mucin 20 Cell Surface Associated) • MUC17 (Mucin 17) • MUC6 (Mucin 6)
    |
    TMB-H • MUC16 mutation • MUC5B mutation
    12ms
    Clonal Somatic Mutations in Chronic Lung Diseases Are Associated with Reduced Lung Function. (PubMed, Am J Respir Crit Care Med)
    Our identification of an increased prevalence of clonal somatic mutation in diseased lungs that correlates with airway epithelial gene expression and disease severity highlights for the first time the role of somatic mutational processes in lung disease genetics.
    Journal • Tumor mutational burden
    |
    TMB (Tumor Mutational Burden) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming)
    |
    MUC5B mutation
    1year
    Immune-related gene-based model predicts the survival of colorectal carcinoma and reflected various biological statuses. (PubMed, Front Mol Biosci)
    Enriched pathway analyses showed that cancer-related pathways, including immune-related pathways, were significantly activated in high-score samples and that some drugs have significantly lower IC values than those with low score. The model developed based on immune-related genes is robust and reflected various statuses of CRC and may be a potential clinical indicator.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8) • PD-1 (Programmed cell death 1) • CD4 (CD4 Molecule) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming)
    |
    PD-L1 expression • MUC5B mutation
    1year
    Elucidating the molecular role of MUC5B in progressive lung adenocarcinoma: Prospects for early diagnosis. (PubMed, J Mol Recognit)
    Our study concludes by highlighting the functional role of O-glycosylated and mutant MUC5B in promoting LUAD by immune suppression. Further, clinical gene expression validation of MUC5B suggests its potential role as a diagnostic biomarker for LUAD metastasis.
    Journal
    |
    MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming)
    |
    MUC5B mutation
    1year
    The heterogeneity and clonal evolution analysis of the advanced prostate cancer with castration resistance. (PubMed, J Transl Med)
    Our findings revealed potential genetic regulators to predict the castration resistance and provide insights into the castration resistance processes in advanced prostate cancer. The crosstalk between clonal evolution patterns and tumor microenvironment may also play a role in castration resistance. A multicenter-research including larger populations with different background are needed to confirm our conclusion in the future.
    Journal • Tumor mutational burden • Metastases
    |
    TMB (Tumor Mutational Burden) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming)
    |
    MUC5B mutation
    over2years
    Identification of Muc5B mutation as a positive predictive biomarker for mTORC1/2 inhibition by ATG-008 in lung cancer (AACR 2022)
    These results suggest that the presence of MUC5B mutation correlates with more potent anti-tumor efficacy of ATG-008, potentially serving as a positive predictive biomarker for patient enrichment that warrants further investigation in the clinic.
    STK11 (Serine/threonine kinase 11) • NFE2L2 (Nuclear Factor, Erythroid 2 Like 2) • RICTOR (RPTOR Independent Companion Of MTOR Complex 2) • MUC5B (Mucin 5B, Oligomeric Mucus/Gel-Forming)
    |
    STK11 mutation • NFE2L2 mutation • RICTOR amplification • MTOR mutation • MUC5B mutation
    |
    onatasertib (ATG-008)